Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1

Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response ra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational oncology 2019-05, Vol.12 (7), p.987-995
Hauptverfasser: Chen, Qingfeng, Wang, Jiaxu, Liu, Wai Nam, Zhao, Yue
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 995
container_issue 7
container_start_page 987
container_title Translational oncology
container_volume 12
creator Chen, Qingfeng
Wang, Jiaxu
Liu, Wai Nam
Zhao, Yue
description Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo .
doi_str_mv 10.1016/j.tranon.2019.04.020
format Article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6529825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6529825</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_65298253</originalsourceid><addsrcrecordid>eNqljjFOAzEQAC0klATCDyj8gRivnTvhhoIASgokivTWkttcHJ3XJ_uMBK-HgoaaaoqRRiPELWgFGtq7s5oycmJlNDil10obfSEW4Gy7aoy1c3FVylnrFpwxMzG3AAbWDhbicYN8oCx3MVZO04kyjoGKRO7ktkbk8EWdfE21kHzKtZd7KlPgXr4NOB1TjgWW4vKIQ6GbX16Lh5fn_Wa7Gut7pO5A_DM3-DGHiPnTJwz-r-Fw8n368G1j3L1p7L8D38QlWSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Qingfeng ; Wang, Jiaxu ; Liu, Wai Nam ; Zhao, Yue</creator><creatorcontrib>Chen, Qingfeng ; Wang, Jiaxu ; Liu, Wai Nam ; Zhao, Yue</creatorcontrib><description>Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo .</description><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1016/j.tranon.2019.04.020</identifier><identifier>PMID: 31121491</identifier><language>eng</language><publisher>Neoplasia Press</publisher><subject>Review article</subject><ispartof>Translational oncology, 2019-05, Vol.12 (7), p.987-995</ispartof><rights>2019 The Authors 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529825/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529825/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Chen, Qingfeng</creatorcontrib><creatorcontrib>Wang, Jiaxu</creatorcontrib><creatorcontrib>Liu, Wai Nam</creatorcontrib><creatorcontrib>Zhao, Yue</creatorcontrib><title>Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1</title><title>Translational oncology</title><description>Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo .</description><subject>Review article</subject><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqljjFOAzEQAC0klATCDyj8gRivnTvhhoIASgokivTWkttcHJ3XJ_uMBK-HgoaaaoqRRiPELWgFGtq7s5oycmJlNDil10obfSEW4Gy7aoy1c3FVylnrFpwxMzG3AAbWDhbicYN8oCx3MVZO04kyjoGKRO7ktkbk8EWdfE21kHzKtZd7KlPgXr4NOB1TjgWW4vKIQ6GbX16Lh5fn_Wa7Gut7pO5A_DM3-DGHiPnTJwz-r-Fw8n368G1j3L1p7L8D38QlWSw</recordid><startdate>20190520</startdate><enddate>20190520</enddate><creator>Chen, Qingfeng</creator><creator>Wang, Jiaxu</creator><creator>Liu, Wai Nam</creator><creator>Zhao, Yue</creator><general>Neoplasia Press</general><scope>5PM</scope></search><sort><creationdate>20190520</creationdate><title>Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1</title><author>Chen, Qingfeng ; Wang, Jiaxu ; Liu, Wai Nam ; Zhao, Yue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_65298253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Qingfeng</creatorcontrib><creatorcontrib>Wang, Jiaxu</creatorcontrib><creatorcontrib>Liu, Wai Nam</creatorcontrib><creatorcontrib>Zhao, Yue</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Qingfeng</au><au>Wang, Jiaxu</au><au>Liu, Wai Nam</au><au>Zhao, Yue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1</atitle><jtitle>Translational oncology</jtitle><date>2019-05-20</date><risdate>2019</risdate><volume>12</volume><issue>7</issue><spage>987</spage><epage>995</epage><pages>987-995</pages><eissn>1936-5233</eissn><abstract>Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo .</abstract><pub>Neoplasia Press</pub><pmid>31121491</pmid><doi>10.1016/j.tranon.2019.04.020</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1936-5233
ispartof Translational oncology, 2019-05, Vol.12 (7), p.987-995
issn 1936-5233
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6529825
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Review article
title Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Immunotherapies%20and%20Humanized%20Mouse%20Drug%20Testing%20Platforms1&rft.jtitle=Translational%20oncology&rft.au=Chen,%20Qingfeng&rft.date=2019-05-20&rft.volume=12&rft.issue=7&rft.spage=987&rft.epage=995&rft.pages=987-995&rft.eissn=1936-5233&rft_id=info:doi/10.1016/j.tranon.2019.04.020&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6529825%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31121491&rfr_iscdi=true